Treatment of neurological complications in patients with type 2 diabetes mellitus at the stage of rehabilitation after COVID-19

Main Article Content

V.I. Pankiv

Abstract

Although the predominant clinical manifestation of COVID-19 is a respiratory disease, various neurological symptoms are increasingly being diagnosed, in particular, diabetic polyneuropathy is diagnosed in most patients with diabetes, affecting large and small nerve fibers. Drugs that are traditionally used for neuropathic pain (tricyclic antidepressants, gabapentinoids, etc.), despite their positive effect in eliminating the symptoms of polyneuropathy, often cause side effects and do not impact nerve regeneration. Over the last decade, a group of nucleotides has been used quite actively. Additional information on the effects of this group of drugs was accumulated and there is a gradual transformation, including their compositions. Thus, recently the attention of researchers has been devoted to the study of the effectiveness of the combination of uridine, choline, vitamins B1, B6, B12, and folic acid, which is characterized by a fairly high safety profile and regenerative potential. The review highlights the mechanisms of action and results of clinical use of this combination. Uridine monophosphate, B vitamins, folic acid are involved in metabolic processes, enhancing nerve regeneration. This contributes to the development of indirect (secondary) anal­gesic effect. In addition, the data of new studies indicate the ability of uridine monophosphate derivatives to impact purinergic P2Y receptors, which causes a direct analgesic and direct regenera­tive effect. Studies have demonstrated the clinical efficacy of this combination in the main types of peripheral neuropathic pain. The combination did not cause side effects and was well tolera­ted. There was a reduction or complete withdra­wal of concomitant analgesics against the background of improving the quality of life of patients. The combination of uridine, choline, vitamin B1, vitamin B6, vitamin B12, and folic acid is a very effective addition to the standard therapy of peripheral neuropathic pain of various genesis and rehabilitation after COVID-19.

Article Details

How to Cite
Pankiv, V. “Treatment of Neurological Complications in Patients With Type 2 Diabetes Mellitus at the Stage of rehabilitation After COVID-19”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 17, no. 6, Dec. 2021, pp. 491-5, doi:10.22141/2224-0721.17.6.2021.243214.
Section
Literature Review

References

Peric S, Stulnig TM. Diabetes and COVID-19: Disease-Management-People. Wien Klin Wochenschr. 2020 Jul;132(13-14):356-361. doi:10.1007/s00508-020-01672-3.

Whittaker A, Anson M, Harky A. Neurological Manifestations of COVID-19: A systematic review and current update. Acta Neurol Scand. 2020 Jul;142(1):14-22. doi:10.1111/ane.13266.

Cariou B, Hadjadj S, Wargny M, et al; CORONADO investigators. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020 Aug;63(8):1500-1515. doi:10.1007/s00125-020-05180-x.

Klonoff DC. The Coronavirus 2019 Pandemic and Diabetes: An International Perspective. J Diabetes Sci Technol. 2020 Jul;14(4):703-704. doi:10.1177/1932296820933075.

Mullol J, Alobid I, Mariño-Sánchez F, et al. The Loss of Smell and Taste in the COVID-19 Outbreak: a Tale of Many Countries. Curr Allergy Asthma Rep. 2020 Aug 3;20(10):61. doi:10.1007/s11882-020-00961-1.

Maury A, Lyoubi A, Peiffer-Smadja N, de Broucker T, Meppiel E. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians. Rev Neurol (Paris). 2021 Jan-Feb;177(1-2):51-64. doi:10.1016/j.neurol.2020.10.001.

Garg RK. Spectrum of Neurological Manifestations in Covid-19: A Review. Neurol India. 2020 May-Jun;68(3):560-572. doi:10.4103/0028-3886.289000.

Abenza-Abildúa MJ, Ramírez-Prieto MT, Moreno-Zabaleta R, et al. Neurological complications in critical patients with COVID-19. Neurologia (Engl Ed). 2020 Nov-Dec;35(9):621-627. English, Spanish. doi:10.1016/j.nrl.2020.07.014.

Román GC, Spencer PS, Reis J, et al; WFN Environmental Neurology Specialty Group. The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries. J Neurol Sci. 2020 Jul 15;414:116884. doi:10.1016/j.jns.2020.116884.

Helms J, Kremer S, Merdji H, et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020 Jun 4;382(23):2268-2270. doi:10.1056/NEJMc2008597.

Demeco A, Marotta N, Barletta M, et al. Rehabilitation of patients post-COVID-19 infection: a literature review. J Int Med Res. 2020 Aug;48(8):300060520948382. doi:10.1177/0300060520948382.

Malik RA. Diabetic neuropathy: A focus on small fibres. Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3255. doi:10.1002/dmrr.3255.

Dubbioso R, Nobile-Orazio E, Manganelli F, et al; SIN, SINC and ASNP. Dealing with immune-mediated neuropathies during COVID-19 outbreak: practical recommendations from the task force of the Italian Society of Neurology (SIN), the Italian Society of Clinical Neurophysiology (SINC) and the Italian Peripheral Nervous System Association (ASNP). Neurol Sci. 2020 Jun;41(6):1345-1348. doi:10.1007/s10072-020-04448-9.

Brugliera L, Spina A, Castellazzi P, et al. Nutritional management of COVID-19 patients in a rehabilitation unit. Eur J Clin Nutr. 2020 Jun;74(6):860-863. doi:10.1038/s41430-020-0664-x.

Shakoor H, Feehan J, Mikkelsen K, et al. Be well: A potential role for vitamin B in COVID-19. Maturitas. 2021 Feb;144:108-111. doi:10.1016/j.maturitas.2020.08.007.

Alschuler L, Chiasson AM, Horwitz R, et al. Integrative medicine considerations for convalescence from mild-to-moderate COVID-19 disease. Explore (NY). 2020 Dec 23:S1550-8307(20)30417-1. doi:10.1016/j.explore.2020.12.005.

Wee AKH. COVID-19's toll on the elderly and those with diabetes mellitus - Is vitamin B12 deficiency an accomplice? Med Hypotheses. 2021 Jan;146:110374. doi:10.1016/j.mehy.2020.110374.

Kwok S, Adam S, Ho JH, et al. Obesity: A critical risk factor in the COVID-19 pandemic. Clin Obes. 2020 Dec;10(6):e12403. doi:10.1111/cob.12403.

Ersöz A, Yılmaz TE. The association between micronutrient and hemogram values and prognostic factors in COVID-19 patients: A single-center experience from Turkey. Int J Clin Pract. 2021 Jun;75(6):e14078. doi:10.1111/ijcp.14078.

Gorji A, Khaleghi Ghadiri M. Potential roles of micronutrient deficiency and immune system dysfunction in the coronavirus disease 2019 (COVID-19) pandemic. Nutrition. 2021 Feb;82:111047. doi:10.1016/j.nut.2020.111047.

Acklin S, Xia F. The Role of Nucleotide Excision Repair in Cisplatin-Induced Peripheral Neuropathy: Mechanism, Prevention, and Treatment. Int J Mol Sci. 2021 Feb 17;22(4):1975. doi:10.3390/ijms22041975.

Zhang Y, Guo S, Xie C, Fang J. Uridine Metabolism and Its Role in Glucose, Lipid, and Amino Acid Homeostasis. Biomed Res Int. 2020 Apr 14;2020:7091718. doi:10.1155/2020/7091718.

Srivastava R, Cao Z, Nedeva C, et al. BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammals. Proc Natl Acad Sci U S A. 2019 Jul 30;116(31):15469-15474. doi:10.1073/pnas.1904523116.

Goldberg H, Mibielli MA, Nunes CP, et al. A double-blind, randomized, comparative study of the use of a combination of uridine triphosphate trisodium, cytidine monophosphate disodium, and hydroxocobalamin, versus isolated treatment with hydroxocobalamin, in patients presenting with compressive neuralgias. J Pain Res. 2017 Feb 15;10:397-404. doi:10.2147/JPR.S123045.

Baumel BS, Doraiswamy PM, Sabbagh M, Wurtman R. Potential Neuroregenerative and Neuroprotective Effects of Uridine/Choline-Enriched Multinutrient Dietary Intervention for Mild Cognitive Impairment: A Narrative Review. Neurol Ther. 2021 Jun;10(1):43-60. doi:10.1007/s40120-020-00227-y.

Yakupov EZ. Adjuvant therapy of pain syndromes: possibilities of using nucleotides. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(10):141-145. doi:10.17116/jnevro2019119101141. (in Russian).

Negrão L, Nunes P; Portuguese Group for the Study of Peripheral Neuropathy. Uridine monophosphate, folic acid and vitamin B12 in patients with symptomatic peripheral entrapment neuropathies. Pain Manag. 2016;6(1):25-9. doi:10.2217/pmt.15.60.

Negrão L, Almeida P, Alcino S, et al. Effect of the combination of uridine nucleotides, folic acid and vitamin B12 on the clinical expression of peripheral neuropathies. Pain Manag. 2014 May;4(3):191-6. doi:10.2217/pmt.14.10.

Romanenko VI. Use of the natural compound of uridine in the therapy of chronic pain with manifestations of neuropathy. International Neurological Journal. 2020;16(2):70-75. doi:10.22141/2224-0713.16.2.2020.200966. (in Ukrainian).

Urasaki Y, Pizzorno G, Le TT. Chronic Uridine Administration Induces Fatty Liver and Pre-Diabetic Conditions in Mice. PLoS One. 2016 Jan 20;11(1):e0146994. doi:10.1371/journal.pone.0146994.

Ka T, Inokuchi T, Tamada D, et al. Relationship between plasma uridine and urinary urea excretion. Metabolism. 2010 Mar;59(3):441-5. doi:10.1016/j.metabol.2009.07.032.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 12 > >>